Does Medicare cover Ozempic?

Short answer

Medicare Part D covers Ozempic for type 2 diabetes. Medicare Part D covers Wegovy — a higher-dose semaglutide — for adults with cardiovascular disease and overweight or obesity, following a 2024 FDA approval. Medicare does not cover either drug for weight loss alone. The $2,000 Part D out-of-pocket cap applies in 2026.

The rule that governs GLP-1 coverage under Medicare

The Medicare Modernization Act prohibits Part D from covering drugs “when used for anorexia, weight loss, or weight gain.” Per an independent GLP-1 Medicare coverage analysis: “Medicare is legally prohibited from covering weight loss medications.”

That single rule shapes Medicare coverage of every GLP-1 drug:

• Ozempic (semaglutide, diabetes brand): covered for type 2 diabetes.
• Wegovy (semaglutide, weight-management brand): covered only for the March 2024 FDA-approved cardiovascular indication (see below), not for weight loss alone.
• Mounjaro (tirzepatide, diabetes brand): covered for type 2 diabetes.
• Zepbound (tirzepatide, weight-management brand): covered only for the December 2024 FDA-approved obstructive sleep apnea indication in adults with BMI ≥30; not for weight loss alone.

Ozempic for type 2 diabetes

The GLP-1 Medicare coverage analysis states: “Ozempic/Mounjaro for type 2 diabetes may be covered under regular Part D or MA drug benefits with a matching prescription.”

What the beneficiary needs:

• A documented type 2 diabetes diagnosis (typically ICD-10 E11.x codes).
• A prescription with type 2 diabetes as the indication. The pharmacist and plan will match the diagnosis to the prescription.
• A Medicare Part D plan or an MA-PD plan that has Ozempic on its formulary.

Wegovy for cardiovascular indication (March 2024 approval)

In March 2024, the FDA approved Wegovy for a new indication: reducing the risk of major cardiovascular events in adults with established cardiovascular disease and either overweight or obesity. Because this indication is not weight loss per se, Part D is permitted to cover it.

Per the same analysis: “Wegovy’s recent FDA approval for reducing the risk of heart attack, stroke, or death in adults with overweight or obesity and cardiovascular disease has opened the door for Medicare coverage.”

Requirements:

• Documented cardiovascular disease (prior heart attack, stroke, or diagnosed coronary artery disease).
• BMI ≥27 (overweight) or ≥30 (obesity).
• A prescription that names the cardiovascular indication, not weight loss.

Not every Part D plan has Wegovy on formulary for the CV indication yet. Check the plan’s 2026 formulary.

Cost-sharing

Ozempic and Wegovy are specialty-tier drugs.

• Tier placement: typically Tier 4 (non-preferred brand) or Tier 5 (specialty).
• Deductible: most Part D plans have a deductible ($480+ in 2026 depending on plan).
• Coinsurance: 25-33 percent during the initial phase in most plans.
• The $2,000 out-of-pocket cap. The Inflation Reduction Act sets a $2,000 annual cap on Part D out-of-pocket spending for 2025 and beyond. Once the beneficiary reaches $2,000, the plan pays 100 percent for the rest of the year. GLP-1 users often reach the cap by mid-year given the drug’s high cost.

An MA-PD plan may have a different structure — check the plan’s Evidence of Coverage.

When Ozempic is denied

The most common reasons a Part D plan denies Ozempic:

• The prescription lists weight loss as the indication. The prescriber must document type 2 diabetes.
• The plan requires prior authorization. Many plans require prior auth documentation of the diabetes diagnosis and prior tries of preferred alternatives (metformin, other GLP-1s).
• Step therapy. The plan may require the beneficiary to try a preferred alternative first.
• Formulary exclusion. Some plans do not have Ozempic on formulary; a formulary exception can be requested.

The appeal path:

1. Prescriber-initiated prior authorization. The prescriber submits documentation of the diabetes diagnosis and, if applicable, prior tries.
2. Formulary exception. Beneficiary or prescriber requests plan approval for a non-formulary drug.
3. Part D redetermination. If denied, request a redetermination within 60 days.
4. Independent Review Entity (IRE) reconsideration. If the plan denies the redetermination, the case goes to an independent reviewer.

When a patient advocate helps

• The prescription was denied but the diagnosis is on record. An advocate can review the rejection reason and coordinate with the prescriber to submit the correct documentation.
• Multiple GLP-1s have been tried and stopped. Step-therapy requirements can create loops. An advocate familiar with the specific plan can navigate the exception process.
• The beneficiary has both diabetes and a CV indication. For overlapping indications, an advocate can help identify the optimal prescription pathway.
• The beneficiary is near the $2,000 cap. An advocate can time refills to minimize cash outlay.

Contact Baba Care if a GLP-1 prescription has been denied and the underlying condition qualifies.

Frequently asked questions

Does Medicare cover Ozempic for weight loss? No. Ozempic is only Medicare-covered for its FDA-approved diabetes indication.

Is Wegovy the same as Ozempic? Same molecule (semaglutide), different brands, different doses, different FDA indications. Ozempic is approved for diabetes; Wegovy is approved for weight management and (since March 2024) for cardiovascular risk reduction.

Does Medicare cover Mounjaro? Yes, for type 2 diabetes, on the same rules as Ozempic.

What does the $2,000 out-of-pocket cap actually mean for GLP-1 users? Once the beneficiary has paid $2,000 total out of pocket on Part D drugs in a calendar year, the plan pays 100 percent for the rest of the year. For a GLP-1 user at $200/month copay, that’s about 10 months.

Will Medicare start covering Ozempic for weight loss in the future? Only if the Medicare Modernization Act’s weight-loss exclusion is amended, or if the FDA approves Ozempic for a new indication that would trigger coverage. Neither has happened as of 2026.

About Baba Care. Baba Care is a patient advocacy service supporting families navigating Medicare and complex care decisions.

Medical / financial disclaimer. This article is educational and does not constitute medical, financial, or legal advice.

Additional source references

• FDA · March 2024 approval of Wegovy for cardiovascular risk reduction
• Medicare Modernization Act · statutory Part D exclusion for anti-obesity drugs